An open label, single-dose, single-period study designed to assess the mass balance recovery, metabolite profile and metabolite identification of [14C]encaleret in healthy male subjects
Latest Information Update: 23 Dec 2023
At a glance
- Drugs Encaleret (Primary)
- Indications Hyperparathyroidism; Hypocalcaemia
- Focus Pharmacokinetics
- Sponsors Calcilytix therapeutics
Most Recent Events
- 05 Apr 2023 Status changed from recruiting to completed.
- 05 Apr 2023 Planned End Date changed from 25 Apr 2023 to 27 Apr 2023.
- 23 Mar 2023 Recruitment completion is expected on 27/03/2023 according to ISRCTN registry record.